Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06790784 · ClinicalTrials.gov registry record · Phase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
A Phase 3 study of Proliferative Diabetic Retinopathy (PDR), sponsored by Jaeb Center for Health Research.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
- 20
- Study locations
NCT06790784 is a Phase 3 study of Proliferative Diabetic Retinopathy (PDR) that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 426 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT06790784, a Phase 3 study of Proliferative Diabetic Retinopathy (PDR), is actively recruiting participants, sponsored by Jaeb Center for Health Research.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.
Conditions Studied
Interventions
- DRUG Faricimab
- PROCEDURE Vitrectomy
- DEVICE Endolaser
- DEVICE Panretinal Photocoagulation (PRP)
Study Locations (20)
Florida
- Florida Retina Consultants - Lakeland
- Ophthalmic Partners of Florida, PA dba Central Florida Retina - Orlando
- Retina Associates of Florida, LLC - Tampa
California
- Retina Associates of Southern California - Huntington Beach
- Loma Linda University - Loma Linda
Massachusetts
- Boston Medical Center Corporation - Boston
- Joslin Diabetes Center - Boston
Texas
- Retina Consultants of Texas, PA - Bellaire
- Texas Retina Associates - Lubbock
Georgia
- Southeast Retina Center, P.C. - Augusta
Illinois
- Illinois Retina Associates SC Oak Park Site - Oak Park
Indiana
- Midwest Eye Institute - Carmel
Iowa
- Wolfe Clinic, P.C.- West Des Moines - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2031-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06790784
The ClinicalTrials.gov registry entry for NCT06790784 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proliferative Diabetic Retinopathy (PDR) appearing as the primary indexed condition, and to 4 interventions - of which Faricimab is the first listed.
NCT06790784 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06790784 about?
NCT06790784 is a clinical study titled "Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR". This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as...
What is the current status of trial NCT06790784?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2025-08-04. Estimated completion is 2031-08.
What conditions does trial NCT06790784 study?
This clinical trial studies the following conditions: Proliferative Diabetic Retinopathy (PDR).
What interventions are being tested in trial NCT06790784?
The interventions under investigation include: Faricimab (DRUG), Vitrectomy (PROCEDURE), Endolaser (DEVICE), Panretinal Photocoagulation (PRP) (DEVICE).
Who is sponsoring clinical trial NCT06790784?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06790784 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proliferative Diabetic Retinopathy (PDR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.